TY - JOUR
T1 - Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice
AU - Santiago-Raber, Marie Laure
AU - Dunand-Sauthier, Isabelle
AU - Wu, Tianfu
AU - Li, Quan Zhen
AU - Uematsu, Satoshi
AU - Akira, Shizuo
AU - Reith, Walter
AU - Mohan, Chandra
AU - Kotzin, Brian L.
AU - Izui, Shozo
N1 - Funding Information:
We thank Dr Thomas Moll for critical reading the manuscript and Ms P. Borel, Ms C. Manzin, Mr G. Brighouse, Mr G. Celetta, and Mr G. Sealy for their excellent technical help. This work was supported by grants from the Swiss National Foundation for Scientific Research and from the Alliance for Lupus Research. The authors have no conflicting financial interests.
PY - 2010/6
Y1 - 2010/6
N2 - Accumulating evidence supports the idea that TLR7 and TLR9 play pathogenic and protective roles, respectively, in the development of murine systemic lupus erythematosus (SLE). However, the molecular mechanism responsible for the accelerated development of SLE resulting from the deletion of TLR9 and the respective contributions of TLR7 and TLR9 to the development of different autoimmune responses against nuclear and non-nuclear autoantigens implicated in lupus nephritis have not been well defined. In the present study, we addressed these questions by assessing the effect of the TLR9 and/or TLR7 deletion on the production of various autoantibodies and the development of lupus nephritis in C57BL/6 mice congenic for the Nba2 (NZB autoimmunity 2) locus (B6.Nba2). TLR9-deficient B6.Nba2 mice displayed increased production of autoantibodies against nuclear antigens, serum retroviral gp70 and glomerular matrix antigens, and developed a markedly accelerated form of lupus nephritis. Enhanced disease was associated with functionally upregulated expression of TLR7, as documented by an increased TLR7-dependent activation of B cells and plasmacytoid dendritic cells. Notably, disease exacerbation in TLR9-deficient mice was completely suppressed by the deletion of TLR7. Our results indicate that TLR7 has a pivotal role in a wide variety of autoimmune responses against DNA- and RNA-containing nuclear antigens, retroviral gp70 and glomerular matrix antigens implicated in murine SLE, and that enhanced TLR7 activity is critical for the accelerated development of SLE in TLR9-deficient lupus-prone mice.
AB - Accumulating evidence supports the idea that TLR7 and TLR9 play pathogenic and protective roles, respectively, in the development of murine systemic lupus erythematosus (SLE). However, the molecular mechanism responsible for the accelerated development of SLE resulting from the deletion of TLR9 and the respective contributions of TLR7 and TLR9 to the development of different autoimmune responses against nuclear and non-nuclear autoantigens implicated in lupus nephritis have not been well defined. In the present study, we addressed these questions by assessing the effect of the TLR9 and/or TLR7 deletion on the production of various autoantibodies and the development of lupus nephritis in C57BL/6 mice congenic for the Nba2 (NZB autoimmunity 2) locus (B6.Nba2). TLR9-deficient B6.Nba2 mice displayed increased production of autoantibodies against nuclear antigens, serum retroviral gp70 and glomerular matrix antigens, and developed a markedly accelerated form of lupus nephritis. Enhanced disease was associated with functionally upregulated expression of TLR7, as documented by an increased TLR7-dependent activation of B cells and plasmacytoid dendritic cells. Notably, disease exacerbation in TLR9-deficient mice was completely suppressed by the deletion of TLR7. Our results indicate that TLR7 has a pivotal role in a wide variety of autoimmune responses against DNA- and RNA-containing nuclear antigens, retroviral gp70 and glomerular matrix antigens implicated in murine SLE, and that enhanced TLR7 activity is critical for the accelerated development of SLE in TLR9-deficient lupus-prone mice.
KW - Endogenous retrovirus
KW - Lupus nephritis
KW - Systemic lupus erythematosus
KW - Toll-like receptors
UR - http://www.scopus.com/inward/record.url?scp=77952242576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952242576&partnerID=8YFLogxK
U2 - 10.1016/j.jaut.2009.11.001
DO - 10.1016/j.jaut.2009.11.001
M3 - Article
C2 - 19944565
AN - SCOPUS:77952242576
SN - 0896-8411
VL - 34
SP - 339
EP - 348
JO - Journal of Autoimmunity
JF - Journal of Autoimmunity
IS - 4
ER -